plasma arc discharg real-tim on-demand
inhal nitric oxid therapi closer realiti
initi outperform
view beyond air plasma arc discharg inhal nitric oxid ino technolog
earli stage highli disrupt multipl call option sever therapeut
segment on-demand cylinder-fre ino approach tri reinvent
wheel term specif therapeut titrat certain indic instead
valu proposit make ino avail cost-effect hassle-fre
intuit simpl way sure risk especi regulatori concern
lungfit devic get pma approv bode well share gain
regulatori approv therapeut indic
select pulmonari vasodil ino therapi acut
respiratori condit fda approv half-lif
second solubl hydrophob environ water
enabl rapid diffus across cell membran produc endogen
endothelium promot vasorelax modul platelet function
world-wide ino market current stand ikaria first compani
get ino approv via anda pathway commerci launch ikaria
rapidli grew cylinder-bas ino therapi inomax
got acquir monopoli statu led lack
innov price power
recent event threaten monopoli statu first lost ip
litig praxair privat open door praxair launch cylinder-
base gener ino discount besid lose patent battl
face existenti busi headwind second beyond
plasma arc discharg work way device-bas regulatori
beyond adapt plasma arc discharg ino refin on-demand
product ambient air use key technolog licens nitricgen privat
beyond reinvent wheel new therapeut titrat variou
indic offer simpler approach real-tim on-demand ino
beyond recent outlicens pulmonari hypertens indic
royalti indic bronchiol
nontubercul mycobacteria investig home-us adapt
core technolog also work multipl call option buoy thesi
year price histori xair
beyond develop inhal nitric
oxid use plasma arc discharg
bedsid use hospit
analyst certif import disclosur see disclosur
construct stanc stori predic
lungfit inhal therapi beyond
reinvent wheel provid econom
market leader space wound
recent patent litig loss praxair beyond
lungfit get pma approv contend open
lungfit rapidli gain traction marketplac given
eas use
one indic alreadi out-licens assum
pediatr pulmonari
hypertens likelihood success two call
optionsbronchiol non-tubercul mycobacteria
pma approv receiv
praxair continu domin ino space
beyond distant player
bronchiol ntm non-tubercul mycobacteri indic
least year
compani sign new licens agreement
pma submiss
pma approv commerci launch thereaft
bronchiol ntm
goe bankruptci caus sever disloc
market higher-than-norm share gain beyond partner
praxair introduc ino platform gain traction
lungfit pma approv fda requir new trial rais
object base devic perform advers event
compet ino technolog better receiv
litig loss effect market share price
sell practic
valu beyond use sum part methodolog assum discount rate pphn persist pulmonari hypertens
indic rate bronchiol ntm non-tubercul mycobacteria indic analysi suggest pphn
busi worth least ntm indic worth least lead us pt
dcf pphn assumpt discount rate steadi state beyond discount rate termin year
free termin year
dcf ntm assumpt pphn except discount rate free
regulatori risk far biggest risk stori beyond chart medic devic pathway therapeut segment
tradit drug use hiccup regulatori pathway dramat neg effect stock far
know medic devic pathway never util nitric oxid therapi henc novel signific uncertainti
beyond need signific addit capit fund clinic trial regulatori submiss henc dilut occur time
happen praxair determin larg extent beyond receiv marketplac
see xair stock trade specul appropri risk toler investor
tabl content
clinic evid inhal therapi
toxic inhal
recent develop patent litig
econom ino therapi
inhal nitric oxid ino therapeut agent
nitric oxid signal molecul produc endogen within vascular smooth
muscl cell solubl hydrophob environ water enabl
rapidli diffus across cell membran level produc endotheli cell
bodi facilit synthesi cgmp key protein promot maintain
vasorelax also extens studi biolog effect
maintain vascular integr modul platelet function therapeut potenti
ino first suggest pulmonari hypertens lamb model
select uptak across alveolar capillari membran lung
subsequ increas cgmp product observ vasodil caus led
flurri research next year final lead fda approv ino two
indic pulmonari hypertens newborn hypox failur depend
right-left shunt pulmonari hypertens adult cardiac surgeri
debat ino ino deliveri system
nitric oxid use select pulmonari vasodil acut chronic
respiratori condit gener well accept consid wide therapeut
potenti across varieti condit in-hospit at-hom set current
world-wide sale ino rel minuscul monopoli
space barrier widespread adopt econom current
product acquisit channel fraught high cost averag hospit
neonat icu requir cash outlay averag costs/day ino
rang averag total cost per patient run
high cost mean challeng incur econom justifi start
ino program hospit logist train requir ino integr
part program technician need understand handl high-pressur cylind
practic therapeut band ino rel tight fda approv
use current ppm exact titrat ino remain subject debat
patient get ino differ clinic outcom lack titrat
exacerb fact true long-term random clinic trial
space certain concentr deliv necessarili impli
amount deliv lung actual amount could
lower higher intak expos patient risk higher product nitrogen
dioxid harm ga caus inflamm short life
second abil pass cell membran make uniqu help
pulmonari vasodil howev bind oxyhemoglobin quickli
methemoglobin produc prevent oxygen bind blood thu excess
hamper arteri oxygen clinic final clinic studi shown ino
reduc length hospit stay reduc need ecmo improv pulmonari arteri
oxygen satur time walk test etc ino
studi shown yet improv mortal
market potenti signific
ikaria inc pioneer space first market high-pur ino system use
high-pressur cylind begin ikaria got acquir
sale multipl time current world-wide sale ino
 current account sale grow
compound-annual-growth-rate control roughli share world-wide sole provid
 ino monopoli statu led price environ averag
util hospit neonat icu spend ino
market due dilig indic averag util ino day
increment cost temporari benefit debat clinic
util mention prevent widespread util therapi beyond
nicu outsid price constraint prevent
adopt ever sever estim newborns/yr
persist pulmonari hypertens requir extens care
hospitalizations/yr infant bronchiol patients/yr
sever lung infect could benefit ino therapi reduc econom
burden provid care seem weak link valu chain
beyond air lungfit system util plasma arc technolog real-tim on-demand
closer look beyond air technolog show util method gener ino
well-proven concept last year incorpor certain proprietari
knowledg make widget better note electr arc discharg regularli
use weld applic light ga product beyond licens key
patent nitricgen util proprietari algorithm on-demand product
use frequenc durat electr discharg product ambient
air low energi requir less heat dissip henc cool system requir
abil adapt hospit home set make approach intrigu
view lungfit attempt simplifi logist ino deliveri
also improv econom across board unlik player
praxair liquid aiquy rate beyond plasma arc discharg
technolog file regulatori approv fda medic devic
drug pma applic expect regulatori approv might come
sometim understand beyond attempt gain regulatori
approv manner praxair done drug side use fourier
transform infrar ftir spectroscopi determin level gase intak valv
ventil studi per se requir pma approv first
indicationpersist pulmonari hypertens lead strateg partnership
sign right indic beyond air
devic get pma approv contend would first technolog get non-
cylind base ino approv devic true paradigm chang space
current market dynam bode well beyond
three recent develop present turn point new entrant ino space
dec praxair success invalid key claim mnk patent open
door gener competit price pressur new startup start evalu
differ method gener ino thu present paradigm shift
focu rehospit heart failur pneumonia etc qualiti metric measur
hospit could indirectli help expand use ino user-friendli cost-effect
system avail beyond air lungfit approv could strongli benefit
structur chang marketplac
view beyond air plasma arc discharg ino earli stage though highli
disrupt technolog multipl call option variou therapeut segment on-
demand cylinder-fre ino technolog beyond approv could repres
paradigm shift ino space beyond view tri reinvent wheel
term specif therapeut titrat ino certain indic technolog
valu proposit make ino avail cost-effect hassle-fre
intuit simpl way sure risk regulatori risk greatest pt
deriv use sum part methodolog target opportun discount
composit reflect assess binari outlook next year fda
regulatori risk far biggest risk stori beyond chart medic
devic pathway therapeut segment tradit drug use
hiccup regulatori pathway dramat neg effect stock far
know medic devic pathway never util nitric oxid therapi
novel entail signific uncertainti liquid risk beyond need
signific addit capit fund clinic trial regulatori submiss henc
dilut occur time market risk happen praxair
determin larg extent beyond receiv marketplac
pleas see initi report cry-outperform nvro-perform
vrex-outperform irtc-perform vray-
outperform expand medic devic coverag
beyond earli stage medic devic compani develop lung inhal
nitric oxid deliveri system use ambient air use plasma arc discharg
technolog make new concept beyond attempt
make exist clinic practic less cumbersom equal effect possibl
econom current standard care use medical-grad high-pressur
cylind deliveri consol leader market share
world-wide sale provid easier-to-us on-demand inhal
system beyond attempt reinvent wheel improv first
indic compani proprietari lung devic persist pulmonari
hypertens pphn pma submiss expect soon
beyond air princip product inhal devic cylinder-fre on-demand
nitric oxid gener system util plasma arc technolog produc ambient
air compani expect file pma approv persist pulmonari
hypertens neonat end assum approv
timelin pma approv expect sometim compani recent sign
strateg partnership out-licens right persist
pulmonari hypertens pphn neonat hospit set primarili
chines market explain page arrang provid compani
vital up-front capit continu regulatori activ provid visibl
time variou milestone-bas cash flow pma applic
understand base ftir fourier transform infrar spectroscopi techniqu
identifi chemic composit gase prior inspir also unlik cylinder-bas
inhal provid lungfit devic seek regulatori approv via pma
rout essenti medic devic compani tri seek pathway use
inogen concentr predic devic guidanc receiv use
pma pathway submiss pma expect potenti
approv remain unclear fda requir panel product prior
complet primer technic detail product system describ
page report note compani work variou addit
indic ntm nontubercul mycobacteria bronchiol approv
indic expect till beyond portabl titrat monitor
system deliv lungfit measur level aeronox system
manufactur intern biomed privat note aeronox system
current approv use ino ppm
exhibit inhal deliveri system pulmonari hypertens lungfit ntm devic
nitric oxid product use inhal therapi investig
decad commerci product cylind usual base reaction
sulphur dioxid nitric acid reaction sodium nitrit sulfur acid
oxid ammonia platinum catalyst high temperatur
anaerob environ store sever year howev need on-
demand nitric oxid acut chronic respiratori diseas led innov
research field plasma arc discharg product fundament issu
fixat whether product fertil energi requir
break tripl bond nitrogen atom one way provid energi
plasma arc discharg schemat plasma arc discharg necessarili one
use beyond system shown
exhibit schemat sampl plasma arc discharg system product
typic plasma arc discharg system product system util sourc
electr gener electr arc across pair electrod separ air
gap continu introduc air input port electr arc chamber
contain electrod inhal electr circuit suppli high
voltag potenti electrod wherein high voltag potenti peak valu
enough induc electr arc across air gap arc discharg produc
produc mix air dispens output port differ configur
plasma arc discharg system employ differ configur
electrod made two axial align metal rod tip separ
adjust air gap place arc chamber circuitri system could includ
high voltag step-up transform primari coil connect electr power
suppli parallel circuit connect parallel secondari high voltag coil
transform high voltag circuit take ac power primari coil
step voltag peak voltag enough induc electr arc across
electrod air gap system capacitor secondari side
transform charg breakdown voltag subsequ discharg
across gap breakdown voltag reach initi system develop
high voltag discharg creat excess high temperatur lead electrod
electrod wear chang gap arc caus higher level
produc later problem high energi arc discharg erod
electrod address control current across air gap low level
produc glow discharg produc glow discharg gener
initi lower current level reduc electrod gap reduc pressur
chamber even later system develop use dielectr barrier cover one
electrod avoid electrod wear catalyst also introduc facilit
product high temperatur ensu problem high energi
requir run chamber cool ga produc suffici
allow inhal patient inhal purifi devic almost
alway present remov low level produc arc chamber
purifi devic locat ga leav arc chamber forc
purifi devic releas inhal
exhibit chemic reaction catalyz plasma arc discharg
beyond understand licens key gener patent nitricgen
inc patent among other note key specif inner
work lungfit frequenc voltag rfid sensor durat discharg etc
known us howev construct devic base patent licens
nitricgen claim specif made includ
amount gener directli proport frequenc
durat electr puls discharg either one combin
two provid wide control rang product
electron control circuit start electr discharg puls short phase
high voltag initi ioniz gase allow electr current start flow
across electrod gap follow second phase puls
lower voltag current
first high-voltag phase puls kept small period time
enough allow electr current flow gap second phase
puls voltag current reduc lower valu phase
correspond adjust durat phase electr puls discharg
major produc phase
intermitt puls oper control frequenc durat
control predominantli low current provid benefit includ produc
need applic without need addit diluent gase produc
without signific increas temperatur ga therefor elimin
need cool system significantli reduc electrod wear
anoth claim nitricgen patent use magnet field across
electrod gap use either electr coil perman magnet creat magnet
field perpendicular gap puls set author claim
increas produc electr discharg
key aspect patent claim use rfid chip outlet filter
proprietari know-how filter provid novel way filter tell
user filter approach expiri limit may also stop deliv
filter expir biolog system sensit level
final patent make claim variou circuit control featur accur
exhibit order output chang frequenc durat effect magnet output
filter effici
absorpt soda lime filter
soda lime filter commonli use inhal therapi soda lime filter composit
depend make manufactur gener speak filter contain
color indic ethyl violet inact condit
rel ratio individu ingredi vari manufactur respect
applic larg compon note filter
differ specif use life base report condit henc
subsect referenc within context soda lime filter
work necessarili exact filter use beyond system
interest articl british journal anesthesia author ishib et al conduct
set experi efficaci soda lime filter remov harm gase
inhal therapi use commerci avail soda lime filter time
note filter effici improv significantli last year expos
six differ ga mixtur hypox carrier ga minut six
ga mixtur prepar mix follow three gase ppm
ppm air pure final mixtur ratio follow
ga mixtur pass column fill soda lime blank
column control studi flow rate min conduct
chemiluminesc analyz concentr obtain subtract
read read test ga contain result
exhaust soda lime filter shown exhibit find studi
soda lime filter absorb complet combin
absorb present
coexist howev nearli equimolecular amount
absorb absorb
absorb complet concentr higher
color soda lime chang depend amount oxid took place
chemiluminesc reaction show presenc nitrat nitrit
author propos follow chemic reaction explain absorpt
respect soda lime filter depend composit level
exhibit possibl chemic reaction account absorpt inhal therapi devic
ishib et al british journal anesthesia volume
one filter presenc nitrit confirm nitrat author
hypothes strong alkalin specif filter inhibit nitrat format
howev gener nitrat couldnt rule even detect
detect test semi-quantit
react convert rapidli absorb soda
final author conclud soda lime effect absorpt hale
exhibit chang black white concentr exposur soda lime
ishib et al british journal anesthesia volume
uncharg radic molecul time solubl hydrophob
environ water enabl rapidli diffus across cell membran
rel short half-lif allow act primarili local environ synthesi
diffus across cell membran specif target cell sever physiolog
properti blood vessel includ vasodil vascular permeabl
antithrombot properti initi bioavail repres central
featur normal vascular phenotyp requir maintain motor tone inhibit
platelet function therebi prevent thrombosi consequ
exhibit regul relax vascular smooth muscl
level produc endotheli cell play key role maintain
vasorelax exert effect vascular smooth muscl cell vsmc
contractil state defin vascular tone produc within cytosol
endotheli cell diffus rapidli adjac vsmc exert paracrin effect
activ solubl guanylyl cyclas increas synthesi guanosin
monophosph cgmp also decreas cytosol concentr
inhibit voltage-g channel activ protein kinas phosphoryl
protein sarcoplasm reticulum well channel reduct
cytosol concentr result inhibit calcium-calmodulin myosin light chain
kinas complex format vsmc promot vasorelax
exhibit factor action affect platelet function
jin et al journal blood medicin
play key role maintain vascular integr blood flow modul
platelet-endotheli interact although platelet play import role hemostat
plug format wound heal hyperact lead vascular thrombosi
clinic sequela platelet normal circul inact state suppress
biochem system prostacyclin ecto-ad pase prostacyclin
main product acid metabol endotheli cell inhibit platelet via camp
depend mechan includ direct inhibit mobil granul
releas respons inhibit platelet function
decreas adp-induc platelet aggreg indirectli inhibit thromboxan
receptor calcium play central role second messeng platelet increas
concentr within platelet lead cytoskelet rearrang shape chang
platelet granul secret ultim result aggreg exert inhibitori
effect platelet via cgmp product secondari adenosin
triphosphatas atpas depend refil store increas stimul
guanylyl cyclas activ result decreas intracellular level inhibit
receptor-medi releas dens tubular system increas rate
extrus decreas entri extracellular environ addit
kinas mediat phosphoryl phosphlamban result lower avail
particip activ aggreg mechan
nitric oxid abil regul cgmp princip determin platelet inhibitori
action mechan cgmp associ inhibit platelet occur includ
decreas intracellular also impair express activ
fibrinogen bind confirm gp iib/iiia decreas platelet bound fibrinogen
hemostat plug format take place platelet must interact one anoth
form crosslink cell surfac receptor therebi lead aggreg fibrinogen
bridg adjac activ platelet via platelet gp iib/iiia integrin receptor cyclic
gmp reduc total amount conform activ receptor platelet surfac
via inhibit thrombin-medi protein result unfavor condit platelet
aggreg result decreas fibrinogen bind shown dose-
depend strongli correl no-depend cgmp product
bioreact
endogen exist close interrel redox form free radic
nitrosonium result oxid nitroxyl anion no-
result reduct redox form distinct chemic
properti reactiv major metabol product aqueou solut nitrit
react molecular oxygen sever reactiv oxygen speci ro
shown includ superoxid anion hydrogen peroxid hydroxyl
radic oh limit bioactiv endotheli cell macrophag sourc
ro react form peroxynitrit oono- peroxynitrit caus cell
apoptosi dna strand breakag activ poly-adenosin diphosph
ribosyltransferas inhibit mitochondri respiratori enzym make
peroxynitrit cytotox varieti experiment system moreov
reduct oh radic react readili decreas
bioavail ro endotheli wall react unsatur fatti acid speci
oxid shown limit bioavail sever mechan
descript beyond scope report
exhibit biolog reaction
jin et al journal blood medicin
key aspect even relev inhal therapi describ next
section rapid inactiv hemoglobin haptoglobin-hemoglobin complex
plasma reaction heme ferrou iron ferric iron form nitrosyl-
hemoglobin form methemoglobin nitrat reaction oxyhemoglobin
predomin pulmonari circul methemoglobin reduc
ferrou hemoglobin erythrocyt net effect reaction determin
microvascular flow oxygen deliveri
mechan action
lung either endogen produc introduc exogen sourc react
varieti cellular target lung lead plethora respons includ
vasorelax bronchodil well inhibit mitochondri respir
inhibit platelet leukocyt activ modul vsmc prolifer
therapeut potenti inhal select pulmonari vasodil suggest
lamb model pulmonari hypertens patient pulmonari hypertens
scaveng hemoglobin hb diffus blood therebi rapidli
inactiv vasodilatori effect inhal limit larg lung
contrast intraven infus vasodil caus system vasodil
exhibit signal pathway lung
inhal travel airway goe area lung
ventil ga exchang take place diffus rapidli across alveolar capillari
membran subjac smooth muscl pulmonari vessel activ solubl
guanyl cyclas seen exhibit enzym mediat mani biolog
effect respons convers gtp cgmp increas
intracellular concentr cgmp relax smooth muscl via sever mechan
select pulmonari circul result rapid hemoglobin-medi
inactiv pass capillari blood stream bound
hemoglobin red blood cell bound hemoglobin creat methemoglobin
longer exert vasodil properti clinic therapeut appli level
blood leav lung exert vasodil effect rest
vessel bodi inhal therefor use tool select vasorelax
lung without system side effect methemoglobin contrast invers
relat carri capac blood higher concentr use
methemoglobin produc thu monitor level methemoglobin import
exhibit inhal alveolar-capillari membran
select action inhal alveolar capillari membran lung yield
increas cgmp product henc vasodil relax vessel turn reduc
pulmonari vascular resist pvr clinic studi provid support
view inhal effect system vascular resist svr profound
effect pvr intrapulmonari distribut ventil blood flow call v/q
ventil perfus match major determin effici transpulmonari
oxygen determin partial pressur oxygen system arteri blood
normal lung low tension constrict vascular bed hypox
region redistribut blood flow toward lung region better ventil
higher alveolar inhal enhanc mechan increas blood flow
well-ventil lung area diseas elev vasomotor tone
vasodilatori effect inhal mark contrast intraven administ
exhibit lead bronchoconstrict
note almost inhal excret within hr nitrat urin blood
level nitrat report increas breath level ppm
inhal low level deem safe react
produc inhal place lung risk produc cellular injuri
oxid epitheli fluid line epitheli compon
onset inflammatori respons format breath depend
concentr inspiratori concentr resid time
gase increas airway reactiv report human exposur low
ppm major clinic toxic due format
methemoglobinemia unlik easili cross cell membran exert
effect extracellularli lung abund protect mechan oxid
damag contain high concentr antioxid damag occur three
convert nitrou nitric acid distal airway directli
damag certain structur function lung cell
free radic gener result protein oxid lipid peroxid
resist infect reduc alter macrophag immun function
reactiv oxygen speci ro form natur product normal metabol
oxygen import role cell signal homeostasi howev
time supplement oxygen use increas metabol stress ro
level increas dramat caus signific damag cell structur
research shown pulmonari vascular damag anim
concentr time depend found injur pulmonari
epithelium caus cellular damag inflamm process activ cytokin
releas result inflammatori cascad commenc inflammatori respons
lead os produc superoxid peroxid hydroxyl radic peroxynitrit
present shown caus alveolar epitheli apoptosi vitro nitrogen
dioxid increas alveolar septal cell turnov lead acceler lung growth vivo
studi found lung growth associ imbal
extracellular matrix composit specif decreas collagen elastin ratio
lung epitheli barrier integr rat shown alter exposur
increas protein permeabl lung endotheli epitheli cell addit
epitheli damag airway found increas tone respiratori
exhibit dose mechan ventil
tobin et al principl mechan ventil edit
research anim human demonstr neg effect acut
chronic exposur concentr ppm effect present
cellular level symptom manifest clinic us epa set ppm
averag annual ppm averag hour two primari
level regul concentr ga may initi caus
mild short breath period hour day victim may suffer
bronchospasm pulmonari edema exposur higher ppm concentr
ga may induc immedi respons subject may includ cough
fatigu nausea choke headach abdomin pain difficulti breath symptom-
free period hour may follow onset pulmonari edema
anxieti mental confus lethargi loss conscious patient surviv
episod may follow sever week later bronchiol obliteran inhal
high concentr ppm rapidli caus burn spasm swell tissu
throat upper airway obstruct death absorpt lead tachycardia
dilat heart chest congest circulatori collaps obstruct bronchiol
may develop day week sever exposur sudden discontinu inhal
caus sever rebound pulmonari hypertens increas intrapulmonari right-
to-left shunt decreas suggest downregul
endogen synthesi and/or elev level inhal
respons part rebound phenomenon although precis underli
mechan remain elucid avoid rebound pulmonari hypertens slow
stepwis reduct inhal concentr recommend
clinic evid ino therapi
highlight key studi conduct use inomax inhal
studi cite studi inomax current leader patient
test clinic trial patient treat cumul last year
cinrgi double-blind rct term near-term neonat ph
hypox respiratori failur primari object studi determin whether
inomax would reduc need ecmo hypox respiratori failur caus
idiopath pphn pneumonia/sepsi rd patient
mean mm hg mean oi cm mm hg randomli
assign receiv either ppm inomax nitrogen ga placebo
addit ventilatori support patient exhibit mm hg ph
wean ppm inomax placebo primari result highlight
exhibit primari endpoint cinrgi
result show significantli fewer neonat inomax group requir ecmo
compar control group vs number death
similar group inomax placebo combin incid death
and/or receipt ecmo decreas inomax group vs
addit inomax group significantli improv oxygen measur
oi alveolar-arteri gradient paramet patient
treat inomax withdrawn studi drug due methemoglobin
nino double-blind random placebo control multicent trial
neonat hypox respiratori failur object studi determin
whether inhal would reduc occurr death and/or initi ecmo
prospect defin cohort term near-term neonat hypox respiratori failur
unrespons convent therapi hypox respiratori failur caus
pulmonari hypertens newborn pphn respiratori distress syndrom
rd infant day age mean day mean mm hg
mean oxygen index oi cm mm hg initi random receiv
without ppm day respons
studi drug defin chang baselin minut start
treatment full respons mm hg partial mm hg respons mm
hg neonat less full respons evalu respons ppm
control ga primari result nino studi shown
exhibit primari endpoint nino
although incid death day age similar group
control significantli fewer infant group requir ecmo compar
control vs combin incid death and/or initi
ecmo show signific advantag nitric oxid treat group vs
group also significantli greater increas greater
decreas oi alveolar-arteri oxygen gradient control group
paramet significantli patient least partial respons
initi administr studi drug group control group
infant respond ppm nitric oxid control similar
percentag no-treat control patient least partial
respons ppm inhal control drug suggest lack addit
benefit higher dose infant studi drug discontinu toxic
inhal detect effect mortal advers event collect
nino trial occur similar incid rate treatment group follow-up exam
perform month infant enrol trial infant
avail follow-up two treatment group similar respect mental
motor audiolog neurolog evalu
inomax heart failur
random control trial earli compar delay use inhal
newborn moder respiratori failur ph object evalu
whether earli treatment inomax could prevent infant moder respiratori
failur develop sever heart failur oi trial open-label center
trial chile compos term near-term infant week gestat heart
failur pphn infant oxygen index
random earli mechan ventil inomax control mechan ventil
alon oi reach control group infant transit inomax
respons seen inomax either group mechan ventil
replac high-frequ oscillatori ventil unlik ecmo
avail chile studi period primari endpoint treatment failur
defin worsen respiratori statu first hr base increas
oi primari endpoint result show control infant
vs infant receiv earli inomax treatment develop oi
within hr patient treat inomax elev blood level
methemoglobin high level ventilatori circuit differ
group incid neonat complic bleed and/or
coagul disord hypotens infect
studi konduri et al
prospect random control double-mask multicent trial
enrol infant week gestat respiratori failur need assist
ventil oi mild moder sever inomax dose
initi ppm simul sham dose dose increas ppm increas
mm hg infant either group transit standard inomax
oi increas primari outcom death day need ecmo
similar group control group inomax group
despit fail primari endpoint infant earli inomax group
mm hg increas respons studi ga initi compar control
group vs none studi infant studi ga wean
discontinu elev methemoglobin level one inomax infant
control infant develop sever grade intraventricular hemorrhag
periventricular leukomalacia seizur occur inomax infant
numer singl center pool analys case studi use inomax
publish delv studi given post-hoc natur
extrapol made pool analys
toxic inhal
inhal travers pulmonari capillari bed combin
hemoglobin level satur combin
predominantli oxyhemoglobin produc methemoglobin nitrat low oxygen
satur combin deoxyhemoglobin transient form nitrosyl hemoglobin
convert nitrogen oxid methemoglobin upon exposur oxygen
within pulmonari system combin produc
respect interact oxyhemoglobin produc methemoglobin nitrat
thu end product nitric oxid enter system circul predominantli
methemoglobin nitrat methemoglobin prevent oxygen bind hemoglobin
lead reduc shown elev methemoglobin level consid
extrem danger disposit investig function time nitric
oxid exposur concentr neonat respiratori failur methemoglobin
methb concentr time profil first hr exposur
ppm inomax shown
exhibit order symptom correl methemoglobin level methemoglobin product vs inomax use
seen exhibit previou page methemoglobin concentr increas
first hour exposur mean methemoglobin level remain
placebo group ppm ppm inomax group reach
approxim ppm inomax group understand methemoglobin
level control also key area focu beyond lungfit system pma
nitrogen dioxid remain key worri inhal therapi
known caus airway inflamm damag lung tissu concentr
breath circuit exce ppm ifu inomax requir decreas
flow
neonat respiratori failur occur approxim live birth respons
one three neonat death review year worth data nation
pediatr medic databas research john hopkin univers document
substanti increas rate hospit children pulmonari
hospit nationwid pulmonari hypertens ph overal doubl
nation hospit charg treat children rise million
billion dollar addit report show major hospit
congenit heart diseas exact incid preval
pediatr pulmonari hypertens pphn well-known netherland
registri data provid incid idiopath pulmonari hypertens ipah
case per million respect pphn report occur per live
birth approxim newborn despit modern treatment
mortal rate remain approxim moder sever form
condit
pphn histor associ children mostli congenit heart
diseas rise number also appear reflect chang type patient
children without congenit heart defect admit ph treatment
data indic pediatr hospit pphn doubl one
discharg one examin show inflation-
adjust nation charg treat condit skyrocket time period
significantli author say mortal
still high popul decreas hospit
moreov research found patient without congenit heart defect
account major pphn hospit compar
patient congenit heart defect surpris analysi
hospit pphn children hospit even though
special center often best equip deal condit
exhibit incid rate within first two year neonat pediatr
bronchiol common children less yr age first year
life incid report depend sever
infect least hospit everi children younger
year age bronchiol classic season disord common
autumn winter sporad case may occur throughout year risk
factor identifi sever infect includ follow histori
prematur less week gestat age age younger month
congenit heart diseas chronic lung ill immunodefici studi
author rivera et al studi incid bronchiol puerto rico tropic
medic health volume emerg depart visit author found
studi period annual proport er visit
hospit due bronchiol increas
respect annual incid rate hospit per privat
insur children month non-rsv bronchiol frequent diagnosi
hospit occur year-round increas significantli august
decemb averag cost per hospit
anoth key target market inhal sever lung infect purpos
report stay away discuss incid specif lung infect whether
pneumonia cystic fibrosi acut respiratori distress syndrom due lower tract
infect etc could target market significantli higher
bronchiol pphn howev clinic outcom approv thereaft
determin shape henc stay away deep dive
inhal nitric oxid select pulmonari vasodil well accept
clinic use varieti respiratori assist indic inomax market leader
approv follow use conjunct ventil support
appropri activ substanc indic
treatment newborn infant week gestat hypox respiratori
failur associ clinic echocardiograph evid pulmonari
hypertens order improv oxygen reduc need
part treatment peri post-op pulmonari hypertens adult
newborn infant infant toddler children adolesc age year
conjunct heart surgeri order select decreas pulmonari arteri
pressur improv right ventricular function oxygen
recommend dose inomax ppm fda approv letter
specif stipul maintain treatment day underli
oxygen desatur resolv neonat readi wean inomax
therapi dose greater ppm recommend
market inhal highli concentr key vendor market
praxair liquid three compani combin control
world-wide market base current number
share inhal nitric oxid type commonli use market ppm
ppm small player tend produc lower puriti product ppm
number show inomax sale y/i
aggreg market seem also grow rang compound-annual-growth-rate entri praxair
market given recent patent invalid wildcard
equat price risk remain key risk space smaller entrant like beyond
could present paradigm shift suppli chain product adopt key limit
factor adopt inhal besid debat appropri level
need inhal high cost therapi estim
hospit afford inhal therapi depend beyond
price product growth rate product adopt could chang dramat
number inhal specif ppm categori
smaller player offer inhal concentr ppm
rel impur varieti delv deeper specif player
offer note world-wide market share sale
praxair note rel smaller player world-wide share
key market shift note praxair get fda approv subsequ
launch line medic grade inhal therapi noxboxi system later
 earli
exhibit order world-wide sale main ino player geograph distribut approx market share
recent develop patent litig
 praxair
acquisit ikaria inc april
allow get foothold respiratori care space
orphan drug design set expir end ikaria leader
inhal space howev sole provid statu lucr econom bound
attract competit
praxair industri gase compani introduc brand medic grade
call noxiv noxboxi system praxair respons inomax subsequ
file patent infring suit praxair alleg violat key
claim inhal patent us patent no
court held bench trial case
begin march praxair simultan alleg key claim patent
invalid patent no
specif claim cover area risk pulmonari edema
children left ventricular dysfunct use ppm inhal treat
pulmonari hypertens wherein need right-to-left shunt identifi
patient candid ppm inhal patient increas risk
pulmonari edema method provid pharmaceut accept ga
cylind contain compress ga form gaseou blend
suppli cylind provid treat neonat diagnost process identifi
neonat hypox respiratori failur candid inhal
treatment ga deliveri devic administ therapi ga sourc valv
actuat control modul ga deliveri devic control amount
ga deliv circuit contain memori devic track amount ga
deliv sensor continu measur amount produc
calibr techniqu alarm feedback product compens output
drift measur sensor
court order issu dec essenti provid across-the-board victori
praxair defend praxair inc met burden prove invalid clear
numer object rais praxair term law natur natur
phenomena abstract idea patent accept court
exampl notion pulmonari edema caus higher level
patient left ventricular dysfunct could definit proven could
simpli determin law natur
expert side plaintiff defend praxair agre
inhal no effect neonat left ventricular dysfunct matter
human physiolog exampl standard observ dysfunct
ventricl combin increas blood flow could caus back-up venou
blood turn edema law natur highlight praxair expert
court accept full
prior art claim link specif dosag therapeut drug physiolog
clinic outcom failur alleg invent concept
leap purport effect inhal outcom neglect mention
human action requir
ppm requir hypox respiratori failur well document prior art
praxair anda advanc two-part non-infring argument respect
noxiv first use noxiv dsir devic could infring claim
mallinckrodt dsir patent noxiv incompat dsir
devic second even praxair cylind reason capabl use dsir
devic use would satisfi devic method claim dsir patent
court agre praxair argument without inomet dsir devic
deliv use praxair cylind court also highlight
intern document confirm dsir devic intend
inde couldnt oper ga cylind inomax cylind
final praxair also highlight sell inomet key
infring claim dsir devic reject court
evid custom modifi input condit make
devic oper certain way
rule indic anoth competitor praxair entri inhal space
shortli price premium market share pressur
econom ino therapi
import distinct need made discuss econom inhal
therapi cylind vs plasma arc method beyond primari reason
cylinder-bas inhal approv drug compar plasma arc
spontan on-demand method product beyond air lungfit current
pathway devic design post-approv lungfit need dedic
reimburs code thu reimburs amount two differ pathway
like end differ bill code cylind base inhal
shown
exhibit bill code cylind base inhal therapi
inhal therapi effect also quit expens current standard care
medic grade cylind along associ train servic equip
acquisit ikaria inc becam sole provid inhal
rate provid underneath base compani report due
dilig call daili charg inhal therapi alon rang
rang averag neonat use inhal day
therefor result increment bill inhal tune
depend condit treat ancillari facil product usag etc
daili cost use inhal negoti hospit hospit basi therefor
vari quit bit
exhibit averag daili cost inhal use cylind day inhal usual use
interest studi huang et al studi sponsor post-hoc
analys conduct compar cost-effect earli initi inhal
ino oxygen index oi delay initi oi either
hospit birth transfer ino hospit via helicopt emerg
servic decis analyt model evalu cost effect
earli initi ino birth hospit vs transfer ino hospit via
time horizon healthcar system perspect model compar
clinic econom outcom associ three scenario
oi level transfer patient anoth hospit ino
oi level transfer patient anoth hospit ino
oi level transfer patient higher level neonat intens
care unit within birth hospit ino
exhibit treatment pathway highlight studi huang et al
assumpt model includ
patient receiv usual care consist via nasal cannula/non-
invas ventil intub mechan ventil high-frequ ventil
consid ino treatment
patient receiv ino fix amount time addit medic
administ hospit would affect clinic endpoint
advers event differ across model arm therefor healthcar
resourc util cost advers event incorpor model
affect model outcom except cost
patient receiv ino hospit birth may still requir transfer
ecmo avail hospit
snapshot rel cost treatment arm treatment type shown
exhibit cost treatment arm type huang studi
result show
total cost per patient lowest ino initi earli hospit
birth follow ino initi earli hospit transfer
initi delay transfer
compar earli initi ino birth hospit delay initi
transfer associ lower ino cost higher hospit ecmo
clinic outcom patient receiv earli ino regardless
transfer transport cost differ group cost save
per patient ino avail birth hospit
earli initi ino birth hospit result cost save per
patient compar late initi ino transfer increas
probabl ecmo-fre surviv thu econom domin
note studi sponsor henc conclus could
suffer bia purpos highlight studi simpli provid
sampl cost ino therapi approv inhal therapi base pivot
random control trial neonat inhal nitric oxid studi group publish
term near-term infant hypox respiratori failur work start
discuss regard cost associ ino deliveri implement
although expens reduc need expens resourc includ
extracorpor membran oxygen ino pre-term anim model demonstr
reduct pulmonari vascular resist improv surfact function stimul
angiogenesi enhanc alveolar format base evid hope
would reduc right ventricular failur well need prolong
respiratori support potenti toxic oxygen level lead reduct ventilator-
induc lung injuri despit consider effort pauciti larg random
double-blind multi-cent clinic trial pediatr hypox respiratori failur although
clear ino transient improv arteri oxygen evid current
demonstr sustain benefit current practic ino still prescrib
pediatr hypox respiratori failur despit high cost mix evid mani
institut provid neonat pediatr care spend excess
ino mani hospit serv primarili adult elimin ino
practic reserv ino select group special oversight switch
altern vasodil effort reduc cost unproven therapi propon
argu current evid base wrong patient popul
may valid given cost treatment margin benefit arteri
oxygen seem unlik clinic trial perform suffici sampl
size patient popul address concern regard ino outsid
huang studi would probabl differ econom outcom beyond
lungfit technolog goe mainstream part reason beyond intend
implement razor-razor blade model razor plasma arc product consol
associ peripher blade replac filter proprietari
rfid chip embed monitor level also prevent system
oper filter expir level higher expect
beyond air develop program focus key indic persist pulmonari
hypertens bronchiol nontubercul mycobacteri ntm lung infect
pphn right china given circassia
alreadi understand trial pphn conduct
lungfit system note compani plan submit pma docket
expect approv sometim remain two indic
bronchiol ntmwill requir pivot studi simpli inhal yet
approv indic drug categori beyond sponsor
studi bronchiol first studi publish pediatr pulmonolog
jan pilot studi present european respiratori
confer er exhibit highlight product develop
schedul beyond
note trial mention conduct use lungfit system
rather conduct use cylind
aim pilot double-blind rct phase iia determin safeti toler
primari outcom efficaci secondari outcom high-dos inhal
treatment infant moder sever bronchiol intermitt inhal
oxygen/air control given hospit infant
productindicationdeveop statuskey dateslungfit phin-hospit use pphn cardiac surgerycommerci system developmentfda pma file launch ce mark brobronchiol pilot phasepivot studi launch slisever lung infect non tubercul mycobacteria patient treat pilot studi higher concentr start at-hom pilot studi self-administr launch bacteri infectionspilot studi initi anticip pseudomona aerugenosalungfit copdexacerb caus type inrfectionproof concept initi anticip home useproof concept initi anticip cfcystic fibrosistri begin xair outperform
acut bronchiol satur methemoglobin level
vital sign monitor
forty-thre infant enrol baselin characterist compar studi
group mean clinic score compris four compon respiratori rate use
accessori muscl wheez crackl room-air satur
control group respect consist moder
sever overal frequenc advers event similar group
repeat inhal result increas inhal level cumul
effect methemoglobin level secondari outcom efficaci measur
length hospit lo hour lo differ group howev
post-hoc analysi subgroup infant hospit median lo
shorter control group
studi phase multicent double-blind rct high-dos inhal
bronchiol
multi-cent double-blind phase clinic trial compris treatment
period hour day follow-up assess subject
age month old acut bronchiol requir in-pati hospit
clinic score screen room-air random ratio receiv
combin standard support treatment hydrat combin ppm
standard support treatment alon treatment schedul includ five
inhal session per day hour maximum inhal session per
subject inhal treatment deliv air/oxygen blender via simpl mask
minimum primari endpoint studi assess whether ppm
administ intermitt via inhal subject age month acut
bronchiol reduc hospit length lo compar standard support
intermitt via inhal reduc time requir achiev sustain
satur room air least hour compar standard support treatment
whether treatment arm reduc time requir achiev clinic improv
clinic score modifi tal score compar standard support treatment final
safeti toler measur advers event also document vaselin
characterist patient shown
exhibit baselin characterist lungfit high-dos bronchiol studi
result studi shown exhibit follow demonstr lo
reduc hour group compar standard treatment group
mean time vs hour respect secondari endpoint time
reduc hour group compar standard treatment
group mean time vs hour respect time reach modifi
tal mtal score reduc hour group compar
treatment-rel sae report methb level remain within
accept rang treatment vital sign includ heart rate respiratori rate bodi
temp blood pressur remain compar group affect
author conclud
acut bronchiol patient intermitt inhal ppm result
clinic signific reduct lo time time clinic score
dose well toler safe patient
exhibit patient respons treatment
competit beyond come inhal cylind technolog
associ train protocol place sinc fda
first approv inhal therapi ikaria inc brief snapshot offer
variou player inhal space shown
inomax therapi first approv treatment term near-term neonat
week respiratori heart failur sinc inomax therapi also
indic use cardiac surgeri treatment peri- post-op
pulmonari hypertens adult children age conjunct heart surgeri
european union inomax contraind children depend right-to-left
shunt key argument made inomax uniqu injector modul inomax
dsir modul identifi individu ventil waveform flow deliv
synchron proport exact dose independ ventil flow pattern
exhibit order inomax cylind system dsir consol dsir flow deliveri pattern
evolv inomax evolv smaller footprint cylinder-bas therapi design
reduc human error potenti autom provid improv technolog
safeti featur reduc time diagnosi treatment quick
autom setup increas number patient set treatment
increas mobil transport eas unlik inomax system total
weight lb cylind weigh excess lb inomax
evolv expect weight lb overal system expect less
cumbersom remain unclear us lower tank size would inher
limit factor therapi especi longer durat requir
praxair inc acquir noxbox ltd compani special manufactur
inhal ga deliveri monitor instrument medic market -base
bedford scientif limit exist praxair supplier financi term transact
disclos noxbox ltd remain headquart provid
rang medic devic in-hospit use one devic noxboxi deliveri
system provid intellig deliveri precis real-tim monitor nitric oxid
touch screen step-by-step guid interfac enabl eas
use perman affix noxboxi system noxmix system intend
deliv continu flow mix line emerg applic
liquid manufactur market kinox brand cylinder-bas inhal
deliveri system exact market share within row clear us
neither key competit advantag
nu-m inc numd otcb develop inhal system hospit
set well portabl system use small cylind high puriti
fda approv yet
exhibit nu-m line inhal product
anoth compani call bellerophon therapeut inc blph nasdaq develop
deliveri system home use bellerophon variou phase trial
inopuls devic on-going although exact mechan product
inopuls clear us best interpret devic small
cartridg deliveri system design portabl inopuls system
also seek nda approv path
third pole privat spin-off massachusett gener hospit
electrod compani two platform product lightweight portabl design
serv bedsid portabl use gener design test
offlin gener in-line gener place directli within inspiratori line
gener use puls electr discharg produc therapeut rang
part per million ga flow rate liters/min produc air
well ga mixtur contain potenti toxic gase
produc plasma includ nitrogen dioxid ozon remov use
calcium hydroxid scaveng third pole recent sign strateg partnership
actelion divis although term deal known us
vero biotech privat compani base atlanta acquir right
predecessor compani develop core product geno llc basi genosyl
deliveri system proprietari reactor cartridg convert ga highli
purifi therapeut convers technolog allow produc small
amount liquid two reactor cartridg contain drug cassett
porou cylindrical-shap size shape slightli elong d-cell
batteri cartridg compris dens blend antioxid polym
materi ga pass reactor cartridg singl oxygen atom
strip away molecul creat surfac area substrat
antioxid bound cartridg equival sever footbal field
innumer collis antioxid contain reactor
cartridg reactor cartridg design extra capac convert significantli
content vial liquid provid redund capac per
cartridg safeti activ drug deliveri system single-us drug cassett
insert portabl consol genosyl acut ds wearabl control
genosyl chronic ds user activ cassett metal tube glass vial
punctur releas liquid within metal tube liquid heat
slightli vapor produc ga forc cassett
consol control ga pass intern air pump hous within
consol control first reactor cartridg within cassett
convert ga air stream contain therapeut dose
pass second redund reactor cartridg ad safeti deliv
patient ventil patient use genosylacut ds nasal
cannula mask patient use genosyl chronic ds
primari competitor lungfit see novoteri privat
canadian compani develop cylinder-bas inhal therapi call thiolanox
cystic fibrosi also numer competitor biopharma side
vasodil drug includ nitrat prostacyclin analogu inhibitor
endotheli receptor antagonist system drug direct competitor
inhal deliveri system lungfit view also
discuss variou gold-bas silver-bas lipid-bas nanocarri
gener far know preclin stage best
commerci safeti profil in-vivo unknown
beyond recent form strateg partnership plc
specialti pharmaceut compani focus respiratori diseas agreement
provid exclus commerci right beyond lungfit
china right cover potenti indic hospit set administr
inhal ppm includ hypox respiratori failur associ
pphn newborn
term compani agreement beyond grant circassia exclus
licens commerci lungfit use concentr ppm
hospit set china beyond receiv conting payment base
upon achiev certain mileston
payabl immedi share circassia stock
payabl upon success complet pre-submiss meet fda
share circassia stock
payabl upon sooner lungfit us launch pphn day post
payabl upon label expans relat indic us
payabl launch china
addit beyond receiv royalti circassia base upon gross profit
futur sale product till expir applic patent
one-tim royalti first cumul gross profit us
one-tim first cumul gross profit china thereaft
annual gross profit includ us china combin
annual gross profit excess us china combin
royalti paid cash mileston payment either cash
circassia stock mileston payment made circassia stock stock valu
discount last trade price follow expir applic patent
contract call circassia pay beyond royalti annual gross profit
includ royalti annual gross profit exceed
base term contract month end march beyond
met first two mileston receiv share circassia valu
consider alloc first two perform oblig one
transfer ip circassia recogn point time valu
on-going support associ pma submiss
regulatori approv valu record defer
revenu recogn period time commenc agreement
manag expect submit pma defer revenu june
beyond current early-stag compani licens arrang persist
pulmonari hypertens strateg player two indicationsbronchiol
nontubercul mycobacteria ntm requir pivot trial yr
away commerci assum trial success view circassia
partnership vital cash flow infus supplement organ capit rais
compani walk regulatori process pphn hand
commerci rein circassia pphn time beyond continu
lay groundwork pivot trial ntm
burn/month beyond current rang estim
burn increas especi ntm pivot trial come
part spend guesstim could high low given
quarter early-stag natur stori present complex accur
exhibit order market penetr variou indic revenu stratifi indic mm
pro-forma model break revenu stream beyond separ bucket
pphn bronchiol ntm pphn indic involv mileston payment
outlin next page model maximum market penetr
circassia note current structur market
condit may actual much favor beyond given issu face
howev purpos product adopt use new modal believ
prudent model trajectori beyond royalti stream outlin earlier
simpli net mileston payment beyond receiv complement
expenditur capit rais henc npv calcul mileston
payment part wash ntm indic current
model beyond go direct pro-forma assum filter/day price
averag patient indic treat day
mention earlier number day treat rang anywher pphn
indic
key aspect pro-forma estim inher uncertainti risk associ
regulatori approv subsequ commerci launch therefor use sum
part methodolog valu indic moreov presenc
commerci partner pphn necessit rel lower discount rate compar
two indic ntm end npv model pphn util
discount rate ntm indic util discount rate
net effect assumpt pphn franchis
ntm busi total dcf model individu
busi shown page follow
beyond suraj kalia cfafre firm model pphnfiscal year end tax oper net capit chang work free risk free term growth state present valu decemb valu valu termin analysi equiti valu long term growth rateequ outstand valu beyond
beyond airsuraj kalia cfafre firm model brofisc year end tax oper net capit chang work free risk free term growth state present valu decemb valu valu termin analysi equiti valu long term growth rateequ outstand valu xair outperform
beyond suraj kalia cfafre firm model ntmfiscal year end tax oper net capit chang work free risk free term growth state present valu decemb valu valu termin analysi equiti valu long term growth rateequ outstand valu beyond
steven lisi serv beyond air board sinc januari board
ltd wholly-own subsidiari sinc june mr lisi previous senior
vice presid busi corpor develop
avdl instrument restructur compani rais
transform enterpris valu three year prior posit
avadel mr lisi spent year invest global healthcar industri mehta
isali orbim sac capit millennium manag panacea asset manag
deerfield manag mr lisi serv chairman board
mico innov next gener coronari neurovascular stent compani
receiv master intern busi pepperdin univers
amir avniel co-found year experi
lead biotechnolog compani prior co-found rosetta green
eventu acquir monsanto prior rosetta green serv presid
chief execut offic rosetta genom compani studi
comput scienc academ colleg tel aviv jaffa israel earn
bachelor degre social scienc human open univers israel
prior academ studi serv offic israel defens
award four commend excel
dougla beck join chief offic novemb mr beck
chief offic five public compani three
biotechnolog compani mr beck assist compani rais equiti debt
excess million spent four year inc
complet million sale compani mr beck serv new york state
societi cpa chief offic sec committe
duncan fatkin join chief commerci offic januari mr fatkin
success track record global medic devic biopharmaceut industri
build commerci capabl lead market sale team cultiv
strong thought leader relationship across multipl specialti year
experi includ recent role world-wide vice
presid inject diabet zimmer biomet vice presid gener
market reimburs depuy/johnson johnson world-wide vice presid
iorthopaed mr fatkin spent year career europ
asia pacif region last year unit state
initi coverag beyond outperform rate pt
beyond emerg player paradigm-chang technolog inhal
nitric oxid variou respiratori indic compani current pursu uniqu
indic persist pulmonari hypertens pphn bronchiol
nontubercul mycobacteria ntm pphn indic well valid
market leader space beyond licens right
indic circassia up-front mileston payment tune
tier royalti sale china compani pursu
uniqu medic devic pma pathway regulatori approv unlik player
space anda drug approv pathway success technolog
could present uniqu econom clinic logist valu proposit inhal
space simultan beyond pursu indic ntm
regulatori approv would first kind make
compani strong strateg asset conserv model revenu trajectori
three indic sum methodolog use discount rate
pphn indic discount rate ntm indic respect
suggest pphn biz worth least indic worth least
ntm also worth least
risk stori regulatori liquid market risk describ
number except per share
good sold
realiz unreal loss market sec
provis benefit tax
licens right use technolog
loan relat parti
stock issu vendor
liabil relat warrant
stock price compani mention report octob
